Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma and Follicular Lymphoma
First study, at multiple clinical centers, exploring the effects of different combinations of compounds (CC-122, CC-223 ,CC-292 and rituximab) to treat Diffuse Large B Cell Lymphoma (DLBCL) and Follicular Lymphoma
Lymphoma, Large B-Cell, Diffuse
DRUG: CC-122|DRUG: CC-223|DRUG: Rituximab|DRUG: CC-122|DRUG: CC-292|DRUG: Rituximab|DRUG: CC-223|DRUG: CC-292|DRUG: Rituximab
Safety, To determine safety profiles and dose-limiting toxicities of study drug combinations using NCI CTCAE v4., From the time of informed consent, throughout dosing period and for 28 days after the last dose of study drug.
Efficacy, Tumor response rates using Cheson Revised Response Criteria for Malignant Lymphoma, Every 2-3 months until proof of tumor progression|Pharmacokinetics - CC-223 and CC-292 interaction, Area under the plasma concentration-time curve, Day 1, Day 15
Study CC-122-DLBCL-001 is a Phase 1b dose escalation and expansion clinical study of CC 122, CC-223 and CC-292 administered orally as doublets with or without rituximab, in participants with relapsed/refractory DLBCL who have failed standard therapy.

In expansion phase, selected combination will be administered to lenalidomide na√Øve FL participants and lenalidomide exposed FL participants in addition to relapsed/refractory DLBCL participants.